Antimicrobial peptides, pharmaceutical compositions containing antimicrobial peptides, and their applications
By optimizing the amino acid sequence of fish egg yolk high-phosphorus protein-derived peptides, an antimicrobial peptide of 29 amino acids was designed, solving the problems of high synthesis cost and insufficient antibacterial effect, and achieving effective inhibition of multidrug-resistant bacteria. It is applicable to fields such as medicine, clinical treatment and aquaculture.
Patent Information
- Application Number
- CN202111552232.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-12-17
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2041-12-17
AI Technical Summary
Existing fish yolk high-phosphorus protein-derived peptides have problems such as long amino acid sequence length leading to increased synthesis costs, or short sequence length but insufficient inhibitory and killing effects, especially when facing multidrug-resistant bacteria.
An antimicrobial peptide composed of 29 amino acids was designed. Through sequence optimization and site-directed mutagenesis of amino acids, the synthesis cost was reduced and the antibacterial effect against Gram-negative and Gram-positive bacteria was improved, especially the inhibitory ability against multidrug-resistant bacteria.
This antimicrobial peptide maintains high antibacterial activity under extreme conditions and has broad application prospects. It is suitable for fields such as medicine, clinical treatment, food and aquaculture, and has a significant inhibitory effect on multidrug-resistant bacteria.
Smart Images

Figure CN116333083B_ABST
Abstract
Description
Technical Field
[0001] This disclosure pertains to the field of pharmaceutical technology. Specifically, this disclosure relates to an antimicrobial peptide, a composition containing the antimicrobial peptide and its application, a method for inhibiting or killing bacteria, and a method for preventing or treating diseases. Background Technology
[0002] The discovery and use of antibiotics have effectively controlled most infectious diseases. However, decades of overuse have led to antibiotic resistance in pathogens. In recent years, the long-term abuse of antibiotics has resulted in an increasing number of inflammatory diseases caused by drug-resistant strains. Antibiotic residues and bacterial resistance have posed a serious threat to global public health. Currently, the development of new antibiotics is slowing down, the effectiveness of antibiotics is declining, and the problem of multidrug-resistant bacteria is becoming increasingly serious, making it urgent to explore and develop new antimicrobial strategies.
[0003] Antimicrobial peptides are important components of the defense systems of organisms in nature, characterized by their small molecular weight (<10 kDa), cationicity, and amphiphilicity. Currently, various antimicrobial peptides have been isolated from bacteria, fungi, plants, and animals. These peptides exhibit broad-spectrum resistance against bacteria, protozoa, fungi, and viruses, as well as cytotoxicity against tumor cells. Antimicrobial peptides primarily act on the cell membrane of microorganisms, causing perforation and disrupting its integrity, leading to cytoplasmic leakage and thus achieving bactericidal effects. This mechanism differs from that of antibiotics, making it less likely for microorganisms to develop resistance. Based on these characteristics, antimicrobial peptides are becoming a promising alternative to antibiotics, with the potential for widespread application in clinical treatment, pharmaceuticals, animal husbandry, feed, food, and other fields.
[0004] Vitellogenin, composed of phosvitin (Pv) and lipovitellin (Lv), is a molecule transferred from the mother and stored in fish eggs. Both are derived from the hydrolysis of the high-molecular-weight vitellogenin (Vg) and have long been considered essential nutrients stored in the yolk for embryonic growth and development. As a major component of vitellogenin, chicken phosvitin has been reported to inhibit the growth of the Gram-negative bacterium *Escherichia coli*. This inhibition is achieved by its rich phosphorylated serine residues binding to metal ions on the bacterial cell membrane surface, thereby increasing bacterial permeability and facilitating the outflow of intracellular substances. Furthermore, vitellogenin, as a precursor to phosvitin, is also involved in antibacterial activities in the immune defense of fish. Research has found that recombinant zebrafish yolk high-phosphorus protein (rPv) can act as a pattern recognition receptor recognized by bacterial characteristic molecules lipopolysaccharide (LPS), lipoteichoic acid, and peptidoglycan. It can also bind to Gram-negative and Gram-positive bacteria such as Escherichia coli, Aeromonas hydrophila, and Staphylococcus aureus, and can act as a microbial agent to kill these bacteria.
[0005] Reference 1 discloses Pt5, a 55-amino acid peptide from the carboxyl terminus of zebrafish protein v (Pv), which exhibits stronger antibacterial activity and certain immunomodulatory functions than Pv, demonstrating characteristics of an antimicrobial peptide. Pt5e, obtained by targeted point mutation of the amino acid sequence of Pt5, shows even stronger antibacterial properties than Pt5, making it an antimicrobial peptide with good antibacterial efficacy. However, the increased sequence length of Pt5e (55 amino acids) leads to higher production costs. Furthermore, while Pt5e shows good antibacterial effects against *Escherichia coli* and *Staphylococcus aureus* with minimum inhibitory concentrations of 1.2 μM and 1.8 μM respectively, it has not been clearly found to maintain the same antibacterial effect against multidrug-resistant bacteria. Therefore, Pt5e has not yet been applied to the prevention and treatment of drug-resistant bacterial infections, especially multidrug-resistant bacterial infections.
[0006] Reference 2 discloses an antibacterial peptide, Pv26-3, which is a mutant of the parent molecule Pv26 obtained by truncating a high-phosphoprotein sequence. Compared with the antimicrobial peptide Pt5e, Pv26-3 has a significantly shorter amino acid sequence, offering advantages such as lower production costs and easier synthesis. However, the truncated Pv26-3 exhibits a minimum inhibitory concentration (MIC) of over 1.2 mM against both Gram-positive and Gram-negative bacteria, indicating insufficient antibacterial activity.
[0007] References:
[0008] Reference 1, Study on the neutralizing effect of fish egg yolk high-phosphorus protein-derived polypeptides on LPS and the anti-inflammatory mechanism of rhodioloside, Hu Lili, China Doctoral Dissertation Full-text Database, Medical and Health Science and Technology Series, No. 07, pp. E079-9
[0009] Reference 2, CN108570102A Summary of the Invention
[0010] The problem the invention aims to solve
[0011] In view of the problems existing in the prior art, such as the long amino acid sequence length of fish yolk high-phosphorus protein-derived peptides, which leads to increased synthesis costs, or the short sequence length but insufficient inhibitory and bactericidal effects, this disclosure provides an antimicrobial peptide as shown in Formula (I), which consists of 29 amino acids, further shortening the sequence length of fish yolk high-phosphorus protein-derived peptides and effectively reducing the artificial synthesis cost of antimicrobial peptides. Furthermore, the antimicrobial peptide shown in Formula (I) exhibits good antibacterial and bactericidal effects, low environmental sensitivity, and high antibacterial activity under extreme environments, showing broad application prospects as an anti-infective drug.
[0012] Solution for solving the problem
[0013] (1) An antimicrobial peptide of formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof:
[0014] R1-Ser-Arg-Met-X4-Lys-X6-Ala-X8-Ile-Ile-Glu-X 12 -X 13 -Arg-Lys-X 16 -His-Lys-X 19 -Arg-X 21 -Leu-Ala-His-X 25 -Ser-Ala-Thr-Lys-R2(I);
[0015] Among them, R1 is selected from -H or -Ac, and R2 is selected from -NH2 or -OH;
[0016] X4 can be selected from the group consisting of Gly, Thr, Lys, Ser, His, Asn, and Arg.
[0017] X6 selects the group consisting of Phe, Ala, Trp, Leu, Val, Tyr, and Gly;
[0018] X8 selects a group consisting of Ala, Lys, Thr, Arg, Asn, Gln, and His;
[0019] X 12 Choose the group consisting of Gln, Thr, His, Asn, Arg, Gly, and Lys;
[0020] X 13 Choose the group consisting of Val, Tyr, Cys, Ala, Trp, Phe, and Met;
[0021] X 16 Choose the group consisting of Leu, Met, Ala, Trp, Phe, Ile, and Tyr;
[0022] X 19 Choose from the groups consisting of Arg, Lys, Asn, Ser, His, Gln, and Pro;
[0023] X 21 Choose the group consisting of Leu, Ile, Ala, Val, Tyr, Trp, and Phe;
[0024] X 25 Choose the group consisting of Asn, Thr, His, Gln, Arg, Gly, and Lys.
[0025] (2) The antimicrobial peptide according to (1) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein the amino acid sequence of the antimicrobial peptide is shown in any one of SEQ ID NO:1 to SEQ ID NO:9.
[0026] (3) The antimicrobial peptide according to (1) or (2) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein an amino acid at one or more positions of the antimicrobial peptide is linked to a modifying group;
[0027] Optionally, the modified amino acid is linked to any of the following modified molecules: fatty acid, polymer, fluorescent compound, nucleotide, drug molecule, or any combination of two or more of the above.
[0028] (4) The antimicrobial peptide according to (3) or its pharmaceutically acceptable salt, ester or solvate, wherein the drug molecule is linked to lysine residues at any one or more positions of the antimicrobial peptide;
[0029] Optionally, the drug molecule is selected from one or more combinations of the following: antibody, antibody fragment, antibiotic.
[0030] (5) A pharmaceutical composition comprising an antimicrobial peptide as described in any one of (1)-(4) or a pharmaceutically acceptable salt, ester or solvate thereof.
[0031] (6) The pharmaceutical composition according to (5), wherein the pharmaceutical composition further comprises one or more pharmaceutically acceptable carriers;
[0032] Optionally, the pharmaceutically acceptable carrier includes one or more of the following: solvent, solubilizer, cosolvent, emulsifier, flavoring agent, odorant, colorant, binder, disintegrant, filler, lubricant, wetting agent, osmotic pressure regulator, pH regulator, stabilizer, surfactant, and preservative.
[0033] (7) The use of the antimicrobial peptide according to any one of (1)-(4) or a pharmaceutically acceptable salt, ester or solvate thereof, or the pharmaceutical composition according to any one of (5)-(6) in the preparation of a medicament for the prevention or treatment of microbial infections;
[0034] Optionally, the microbial infection is a bacterial infection; optionally, the bacterial infection is selected from Gram-negative bacterial infections or Gram-positive bacterial infections; preferably, the microbial infection is a multidrug-resistant bacterial infection.
[0035] (8) The application according to (7), wherein the microbial infection is an infection of one or more bacteria selected from Escherichia coli, Vibrio anguillarum, Aeromonas hydrophila, Staphylococcus aureus, Bacillus subtilis, Klebsiella pneumoniae, and Acinetobacter baumannii;
[0036] Preferably, the microbial infection is selected from infections caused by one or more of the following microorganisms:
[0037] Escherichia coli(ATCC 25922), Vibrio anguillarum(ATCC 43308), Aeromonashydrophilia 35654(ATCC 35654), Staphylococcus aureus 25923(ATCC 25923), Bacillus subtilis 6633(ATCC 6633), Escherichia coli 577 (ATCC 577), Klebsiellapneumoniae 2182 (ATCC 2182), Acinetobacter baumannii 7225 (ATCC 7225).
[0038] (9) A method for inhibiting or killing bacteria, wherein the method comprises contacting the bacteria with an antimicrobial peptide according to any one of (1)-(4) or a pharmaceutically acceptable salt, ester or solvate thereof, or contacting the bacteria with a pharmaceutical composition according to any one of (5)-(6);
[0039] Optionally, the bacterial infection is selected from Gram-negative bacterial infections or Gram-positive bacterial infections; preferably, the bacteria are multidrug-resistant bacteria;
[0040] Preferably, the bacteria are selected from one or more of the following bacteria: Escherichia coli, Vibrio anguillarum, Aeromonas hydrophila, Staphylococcus aureus, Bacillus subtilis, Klebsiella pneumoniae, and Acinetobacter baumannii.
[0041] More preferably, the bacteria are selected from one or more of the following combinations: Escherichia coli (ATCC25922), Vibrio anguillarum (ATCC 43308), Aeromonas hydrophilia 35654 (ATCC35654), Staphylococcus aureus 25923 (ATCC 25923), Bacillus subtilis 6633 (ATCC6633), Escherichia coli 577 (ATCC 577), Klebsiella pneumoniae 2182 (ATCC 2182), and Acinetobacter baumannii 7225 (ATCC 7225).
[0042] (10) A method for preventing or treating a disease, wherein the method comprises administering to a subject an antimicrobial peptide according to any one of (1)-(4) or a pharmaceutically acceptable salt, ester or solvate thereof, or a pharmaceutical composition according to any one of (5)-(6); preferably, the disease is a disease caused by a microbial infection.
[0043] The effects of the invention
[0044] In some embodiments, this disclosure provides an antimicrobial peptide as shown in Formula (I), which consists of 29 amino acids. Compared with existing fish yolk high-phosphorus protein-derived peptides, it has a shorter amino acid sequence and lower synthesis cost. The antimicrobial peptide shown in Formula (I) exhibits high antibacterial activity, showing broad-spectrum antibacterial and bactericidal effects against both Gram-negative and Gram-positive bacteria, and also has good inhibitory effects against clinically common multidrug-resistant (MDR) bacteria. Furthermore, the antimicrobial peptide provided in this disclosure exhibits good antibacterial effects under conditions such as high temperature, plasma, trypsin, acid, and alkaline treatment, and has high stability, showing broad application prospects in the fields of medicine, clinical treatment, food, and aquaculture.
[0045] In some embodiments, this disclosure can further improve the stability of antimicrobial peptides by modifying the amino terminus of the antimicrobial peptide with an acetyl (-Ac) group and replacing amino acids at specific sites, so that the antimicrobial activity of the antimicrobial peptide does not change significantly under extreme conditions.
[0046] In some embodiments, the method for inhibiting or killing bacteria provided in this disclosure involves contacting bacteria with antimicrobial peptides, utilizing the highly efficient and stable antibacterial and bactericidal activity of the antimicrobial peptides to provide a positive and effective treatment method for infections caused by Gram-negative bacteria, Gram-positive bacteria, and especially drug-resistant bacteria.
[0047] In some embodiments, the methods for preventing or treating diseases provided in this disclosure can be used to prevent or treat infections caused by pathogens such as bacteria, and have important application prospects in clinical treatment. Attached Figure Description
[0048] Figure 1 A three-dimensional structural diagram of the antimicrobial peptide Ac-SK-29 is shown.
[0049] Figure 2-1 The antimicrobial activities of antimicrobial peptides Pt5-1a, Pt5-1b, and Ac-SK-29 against E. coli 25922 and E. coli 25923 are shown. (A) shows the antimicrobial activity of different concentrations of Pt5-1a against E. coli 25922; (B) shows the antimicrobial activity of different concentrations of Pt5-1b against E. coli 25922; (C) shows the antimicrobial activity of different concentrations of Ac-SK-29 against E. coli 25922; (D) shows the antimicrobial activity of different concentrations of Pt5-1a against E. coli 25923; (E) shows the antimicrobial activity of different concentrations of Pt5-1b against E. coli 25923; and (F) shows the antimicrobial activity of different concentrations of Ac-SK-29 against E. coli 25923.
[0050] Figure 2-2 The antimicrobial activities of antimicrobial peptides Pt5-1a, Pt5-1b, and Ac-SK-29 against *V. anguillarum* 43308 and *B. subtilis* 6633 are shown. (G) represents the antimicrobial activity of different concentrations of Pt5-1a against *V. anguillarum* 43308; (H) represents the antimicrobial activity of different concentrations of Pt5-1b against *V. anguillarum* 43308; (I) represents the antimicrobial activity of different concentrations of Ac-SK-29 against *V. anguillarum* 43308; (J) represents the antimicrobial activity of different concentrations of Pt5-1a against *B. subtilis* 6633; (K) represents the antimicrobial activity of different concentrations of Pt5-1b against *B. subtilis* 6633; and (L) represents the antimicrobial activity of different concentrations of Ac-SK-29 against *B. subtilis* 6633.
[0051] Figure 2-3 The antimicrobial effects of antimicrobial peptides Pt5-1a, Pt5-1b, and Ac-SK-29 on A. hydrophila 35654 are shown, where (M) represents the antimicrobial activity test results of different concentrations of Pt5-1a, (N) represents the antimicrobial activity test results of different concentrations of Pt5-1b, and (O) represents the antimicrobial activity test results of different concentrations of Ac-SK-29.
[0052] Figure 3-1 The antimicrobial activities of antimicrobial peptides Pt5-1a, Pt5-1b, and Ac-SK-29 against E. coli 577 and K. pneumoniae 2182 are shown. (A) shows the antimicrobial activity of different concentrations of Pt5-1a against E. coli 577; (B) shows the antimicrobial activity of different concentrations of Pt5-1b against E. coli 577; (C) shows the antimicrobial activity of different concentrations of Ac-SK-29 against E. coli 577; (D) shows the antimicrobial activity of different concentrations of Pt5-1a against K. pneumoniae 2182; (E) shows the antimicrobial activity of different concentrations of Pt5-1b against K. pneumoniae 2182; and (F) shows the antimicrobial activity of different concentrations of Ac-SK-29 against K. pneumoniae 2182.
[0053] Figure 3-2The antibacterial activities of antimicrobial peptides Pt5-1a, Pt5-1b, and Ac-SK-29 against *A. baumannii* 7225 are shown. (G) represents the antimicrobial activity of different concentrations of Pt5-1a, (H) represents the antimicrobial activity of different concentrations of Pt5-1b, and (I) represents the antimicrobial activity of different concentrations of Ac-SK-29.
[0054] Figure 4 The effect of high temperature on the antibacterial properties of the antimicrobial peptide Ac-SK-29 is shown. (A) shows the antibacterial activity of Ac-SK-29 against E. coli 25922 at 50℃; (B) shows the antibacterial activity of Ac-SK-29 against E. coli 25922 at 100℃; (C) shows the antibacterial activity of Ac-SK-29 against S. aureus 25923 at 50℃; and (D) shows the antibacterial activity of Ac-SK-29 against S. aureus 25923 at 100℃.
[0055] Figure 5 The effects of plasma environment on the antimicrobial properties of the antimicrobial peptide Ac-SK-29 were shown. (A) shows the antimicrobial activity of Ac-SK-29 under different conditions: plasma + PBS, E. coli 25922 + PBS, E. coli 25922 + PBS, S. aureus 25923 + PBS, and S. aureus 25923 + plasma. (B) shows the antimicrobial activity of different concentrations of Ac-SK-29 against E. coli 25922 under plasma conditions. (C) shows the antimicrobial activity of different concentrations of Ac-SK-29 against S. aureus 25923 under plasma conditions.
[0056] Figure 6 The effects of acid-base conditions on the antibacterial properties of the antimicrobial peptide Ac-SK-29 are shown. (A) represents preliminary experimental results for E. coli 25922; (B) represents preliminary experimental results for S. aureus 25923; (C) represents the antibacterial activity of different concentrations of Ac-SK-29 against E. coli 25922 under acidic conditions; (D) represents the antibacterial activity of different concentrations of Ac-SK-29 against S. aureus 25923 under acidic conditions; (E) represents the antibacterial activity of different concentrations of Ac-SK-29 against E. coli 25922 under alkaline conditions; and (F) represents the antibacterial activity of different concentrations of Ac-SK-29 against S. aureus 25923 under alkaline conditions.
[0057] Figure 7 The hemolytic properties of the antimicrobial peptide Ac-SK-29 were demonstrated. Detailed Implementation
[0058] definition
[0059] When used in conjunction with the term “comprising” in the claims and / or specification, the words “a” or “an” may mean “one”, but may also mean “one or more”, “at least one”, and “one or more”.
[0060] As used in the claims and specification, the words “comprising,” “having,” “including,” or “containing” mean included or open-ended and do not exclude additional, uncited elements or method steps.
[0061] Throughout the application, the term “about” means: a value includes the standard deviation of the error of the apparatus or method used to determine that value.
[0062] While the disclosure supports the definition of the term "or" as merely a substitute and "and / or", the term "or" in the claims means "and / or" unless expressly stated as merely a substitute or as mutually exclusive among substitutes.
[0063] When used in claims or description, the optional / preferred "numerical range" includes both the numerical endpoints at both ends of the range and all natural numbers covered in the middle of the numerical endpoints relative to the aforementioned numerical endpoints.
[0064] As used in this disclosure, the term "polypeptide" refers to any molecule comprising three or more amino acid residues linked by peptide bonds. Polypeptides according to this application include peptides (e.g., tripeptides, oligopeptides, etc.), and peptides that may contain chemical modifications (e.g., glycosylation (glycopeptides), phosphorylation, hydroxylation, sulfonation, palmitoylation, and disulfide bond formation). Polypeptides may also refer to proteins.
[0065] As used in this disclosure, the term "MIC" refers to the minimum inhibitory concentration.
[0066] The term "drug-resistant bacteria" refers to bacteria that have acquired resistance to certain drugs. Bacterial resistance means that after repeated exposure to a drug, the bacteria's sensitivity to that drug decreases or even disappears, resulting in reduced or even ineffective treatment of the drug. Multidrug-resistant (MDR) bacteria are those that have developed resistance to multiple commonly used antimicrobial drugs simultaneously.
[0067] The term "amino acid" includes natural amino acids, non-natural amino acids, amino acid analogs, and all their D and L stereoisomers.
[0068] The amino acids and their abbreviations and English abbreviations in this invention are as follows:
[0069] Gly G glycine Glu E glutamic acid Ala A alanine Lys K Lysine Val V Valine Gln Q glutamine Leu L Leucine Met M Methionine Ile I Isoleucine Ser S Serine Phe F Phenylalanine Thr T threonine Trp W Tryptophan Cys C Cysteine Tyr Y Tyrosine Pro P proline Asp D Aspartic acid His H Histidine Asn N Asparagine Arg R Arginine
[0070] Unless otherwise specified or marked, the N-terminus and C-terminus of the "peptide," "mutant," or their synonyms described in this invention may each be independently modified or unmodified; wherein the N-terminus may be naked (H-) or chemically modified, and the modifying groups include, but are not limited to: C 1-4 Alkyl, acetyl, formyl, benzoyl, trifluoroacetyl, etc.; the C-terminus can be bare (-OH) or chemically modified, including but not limited to amidation (-NH2).
[0071] As used in this disclosure, the term "wild-type" refers to an object that can be found in nature. For example, a polypeptide or polynucleotide sequence that exists in an organism, can be isolated from a natural source, and has not been intentionally modified by humans in a laboratory is naturally occurring. As used in this disclosure, "naturally occurring" and "wild-type" are synonyms.
[0072] As used in this disclosure, the term "mutant" refers to a polynucleotide or polypeptide that, relative to the "wild type" or "comparative" type, contains altered (i.e., substituted, inserted, and / or missing) amino acids or nucleotides at one or more (e.g., several) positions. Substitution refers to replacing a nucleotide or amino acid occupying a position with a different amino acid. Deletion refers to removing an amino acid occupying a position. Insertion refers to adding an amino acid adjacent to and immediately following the amino acid occupying the position. In this disclosure, "substitution," "replacement," and "alternation" are used interchangeably.
[0073] As used in this disclosure, the terms "sequence identity" and "identity percentage" refer to the percentage of identical (i.e., same) nucleotides or amino acids between two or more polynucleotides or polypeptides. Sequence identity between two or more polynucleotides or polypeptides can be determined by aligning the nucleotide or amino acid sequences of the polynucleotide or polypeptide and scoring the number of positions in the aligned polynucleotide or polypeptide containing the same nucleotide or amino acid residues, comparing this to the number of positions in the aligned polynucleotide or polypeptide containing different nucleotide or amino acid residues. Polynucleotides may differ at a position, for example, by containing different nucleotides (i.e., substitution or mutation) or deleted nucleotides (i.e., nucleotide insertion or deletion in one or two polynucleotides). Polypeptides may differ at a position, for example, by containing different amino acids (i.e., substitution or mutation) or deleted amino acids (i.e., amino acid insertion or deletion in one or two polypeptides). Sequence identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residues by the total number of amino acid residues in the polynucleotide or polypeptide. For example, the percentage of identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residues by the total number of nucleotide or amino acid residues in the polynucleotide or polypeptide and then multiplying by 100.
[0074] In some embodiments, when comparing and aligning two or more sequences or subsequences using sequence comparison algorithms or by visual inspection to measure maximum correspondence, the two or more sequences or subsequences have a “sequence identity” or “percentage of identity” of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of nucleotides. In some embodiments, the sequences are substantially identical along the entire length of any one or two compared biopolymers (e.g., polynucleotides).
[0075] As used in this disclosure, the term "pharmaceuticalally acceptable carrier" refers to an excipient widely used in the pharmaceutical manufacturing industry. The primary purpose of using a pharmaceutically acceptable carrier is to provide a pharmaceutical composition that is safe to use, stable in nature, and / or has specific functionalities, and also to provide a method for dissolving the active ingredient at a desired rate or promoting the effective absorption of the active ingredient in a subject after administration of the drug. Pharmaceutically acceptable excipients can be inert fillers or active ingredients that provide a function to the pharmaceutical composition (e.g., stabilizing the overall pH of the composition or preventing degradation of the active ingredient in the composition). Non-limiting examples of pharmaceutically acceptable carriers include, but are not limited to, solvents, solubilizers, cosolvents, emulsifiers, flavoring agents, odor-enhancing agents, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, pH regulators, stabilizers, surfactants, preservatives, etc.
[0076] In this disclosure, the application method can be varied or modified in any applicable manner to meet the needs of the properties of the drug, the convenience of patients and medical personnel, and other relevant factors.
[0077] As used in this disclosure, the term "pathogen" means a microorganism (including bacteria, viruses, rickettsiae, fungi), parasite, or other vector (microbial recombinants, including hybrids or mutants) that can cause infectious diseases in humans or animals. The term "infectious disease" means a disease caused by a pathogen, including, for example, viral infections, bacterial infections, parasitic infections, or fungal infections.
[0078] As used in this disclosure, the term "disease" or "medical condition" means any disruption to the normal state of an animal or plant body or part thereof, which interrupts or alters the execution of vital functions. It typically manifests as obvious signs and symptoms, usually in response to: (i) environmental factors (such as malnutrition, industrial hazards, or climate); (ii) specific infectious agents (such as bacteria or viruses); (iii) inherent defects in the organism (as genetic abnormalities); and / or (iv) combinations of these factors.
[0079] As used in this disclosure, "treatment" means, after contracting a disease, exposing a subject to (e.g., administering medication) the strains and / or macrophages of the present invention or a pharmaceutical composition containing them (hereinafter also referred to as "the pharmaceutical composition of the present invention"), thereby alleviating the symptoms of the disease compared to when not exposed, without implying the necessity of completely suppressing the symptoms of the disease. Contracting a disease means that the body exhibits symptoms of a disease.
[0080] As used in this disclosure, "prevention" means that, before the onset of a disease, the symptoms of the disease are reduced compared to when the subject is not exposed to the pharmaceutical composition of the present invention, by exposing the subject to (e.g., administering medication) the pharmaceutical composition of the present invention. This does not mean that the disease must be completely suppressed.
[0081] As used in this disclosure, the terms "individual" and "subject" are used interchangeably and refer to mammals. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, an individual is a human.
[0082] Unless otherwise defined or clearly indicated by the context, all technical and scientific terms used in this disclosure have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains.
[0083] Technical solution
[0084] In the technical solutions disclosed herein, the meanings of the nucleotide and amino acid sequence listing numbers are as follows:
[0085] The sequence shown in SEQ ID NO: 1 is the amino acid sequence of the antimicrobial peptide Ac-SK-29;
[0086] The sequence shown in SEQ ID NO: 2 is the amino acid sequence of mutant 1 of the antimicrobial peptide Ac-SK-29;
[0087] The sequence shown in SEQ ID NO: 3 is the amino acid sequence of mutant 2 of the antimicrobial peptide Ac-SK-29;
[0088] The sequence shown in SEQ ID NO: 4 is the amino acid sequence of mutant 3 of the antimicrobial peptide Ac-SK-29;
[0089] The sequence shown in SEQ ID NO: 5 is the amino acid sequence of mutant 4 of the antimicrobial peptide Ac-SK-29;
[0090] The sequence shown in SEQ ID NO: 6 is the amino acid sequence of mutant 5 of the antimicrobial peptide Ac-SK-29;
[0091] The sequence shown in SEQ ID NO: 7 is the amino acid sequence of mutant 6 of the antimicrobial peptide Ac-SK-29;
[0092] The sequence shown in SEQ ID NO: 8 is the amino acid sequence of mutant 7 of the antimicrobial peptide Ac-SK-29;
[0093] The sequence shown in SEQ ID NO: 9 is the amino acid sequence of mutant 8 of the antimicrobial peptide Ac-SK-29.
[0094] Antimicrobial peptides
[0095] This disclosure, through sequence optimization and screening of antimicrobial peptides, yields antimicrobial peptides as shown in formula (I) or their pharmaceutically acceptable salts, esters, or solvates:
[0096] R1-Ser-Arg-Met-X4-Lys-X6-Ala-X8-Ile-Ile-Glu-X 12 -X 13 -Arg-Lys-X 16 -His-Lys-X 19 -Arg-X 21 -Leu-Ala-His-X 25 -Ser-Ala-Thr-Lys-R2(I);
[0097] Among them, R1 is selected from -H or -Ac, and R2 is selected from -NH2 or -OH;
[0098] X4 can be selected from the group consisting of Gly, Thr, Lys, Ser, His, Asn, and Arg.
[0099] X6 selects the group consisting of Phe, Ala, Trp, Leu, Val, Tyr, and Gly;
[0100] X8 selects a group consisting of Ala, Lys, Thr, Arg, Asn, Gln, and His;
[0101] X 12 Choose the group consisting of Gln, Thr, His, Asn, Arg, Gly, and Lys;
[0102] X 13 Choose the group consisting of Val, Tyr, Cys, Ala, Trp, Phe, and Met;
[0103] X 16 Choose the group consisting of Leu, Met, Ala, Trp, Phe, Ile, and Tyr;
[0104] X 19 Choose from the groups consisting of Arg, Lys, Asn, Ser, His, Gln, and Pro;
[0105] X 21 Choose the group consisting of Leu, Ile, Ala, Val, Tyr, Trp, and Phe;
[0106] X 25Choose the group consisting of Asn, Thr, His, Gln, Arg, Gly, and Lys.
[0107] The amino acid sequence of the antimicrobial peptides disclosed herein has the N-terminus of the peptide on the left and the C-terminus on the right. Any amino acid in the antimicrobial peptide can be an L-type or D-type amino acid. This disclosure utilizes the protein physicochemical property analysis platform ProtParam tool, APD3, and an antimicrobial peptide database to analyze the theoretical molecular weight, isoelectric point, and charge of egg yolk high-phosphorus protein peptide (Pt5) and its derived peptides. Using Pt5 peptide as a template, a series of modified peptides were designed through sequence truncation and site-directed amino acid mutagenesis, from which modified peptide 29 with the best antibacterial effect was selected. The peptides in this disclosure can be prepared using any method in the art, such as chemical synthesis or recombinant expression. In some embodiments, the antimicrobial peptides are synthesized using conventional solid-phase synthesis, purified by semi-preparative liquid chromatography, and analyzed and their molecular weight confirmed by LC-MS.
[0108] Pt5 is a polypeptide containing 55 amino acid residues at the carboxyl terminus of zebrafish yolk phosphatase. Previous studies have demonstrated that Pt5 exhibits strong inhibitory activity against bacteria and possesses the physicochemical properties of an antimicrobial peptide. The antimicrobial peptide disclosed in this invention is obtained by modifying the Pt5 polypeptide through a series of steps. Compared to the Pt5 polypeptide, the antimicrobial peptide represented by formula (I) in this invention has a minimum inhibitory concentration (MIC) that is only one-third that of the template peptide, exhibiting enhanced antimicrobial activity and the ability to inhibit drug-resistant pathogens. Furthermore, the shorter sequence length of the antimicrobial peptide represented by formula (I) results in lower chemical synthesis costs, making it suitable for large-scale industrial production. Stability tests show that the antimicrobial activity of the antimicrobial peptide represented by formula (I) remains largely unchanged under high temperature, plasma, acidic, and alkaline conditions, demonstrating good stability.
[0109] In some embodiments, in the antimicrobial peptide represented by formula (I), R1 is -Ac, R2 is -NH2, X4 is Lys, X6 is Trp, X8 is Lys, and X... 12 For Lys, X 13 For Trp, X 16 For Trp, X 19 For Lys, X 21 For Trp, X 25The antimicrobial peptide has the amino acid sequence shown in SEQ ID NO:1. This disclosure reveals that the antimicrobial peptide with the sequence shown in SEQ ID NO:1 (hereinafter referred to as Ac-SK-29) exhibits significant antimicrobial activity against both Gram-positive and Gram-negative bacteria, with a MIC value of only 1.2 μM. Ac-SK-29 also demonstrates significant antimicrobial activity against multidrug-resistant bacteria. The MIC value of Ac-SK-29 shows no significant change under high-temperature treatment at 50°C, as well as under plasma, acidic, alkaline, and trypsin conditions, indicating high stability. Furthermore, Ac-SK-29 does not exhibit significant toxicity to cultured mammalian cells and erythrocytes, demonstrating good biocompatibility.
[0110] In some embodiments, in the antimicrobial peptide represented by formula (I), R1 is -H, R2 is -NH2, X4 is Lys, X6 is Trp, X8 is Lys, and X... 12 For Lys, X 13 For Trp, X 16 For Trp, X 19 For Lys, X 21 For Trp, X 25 The antimicrobial peptide is His. It has the amino acid sequence shown in SEQ ID NO:2. The antimicrobial peptide with the sequence shown in SEQ ID NO:2 (hereinafter referred to as: mutant 1) also has a small MIC value against Gram-positive and Gram-negative bacteria and does not have obvious cytotoxicity, but its antibacterial activity under extreme conditions is reduced compared to Ac-SK-29.
[0111] In some embodiments, in the antimicrobial peptide represented by formula (I), R1 is -Ac, R2 is -NH2, X4 is His, X6 is Phe, X8 is Lys, and X... 12 For Lys, X 13 For Phe, X 16 For Trp, X 19 For Lys, X 21 For Trp, X 25 The antimicrobial peptide is His. It has the amino acid sequence shown in SEQ ID NO:3. The antimicrobial peptide with the sequence shown in SEQ ID NO:3 (hereinafter referred to as: mutant 2) has high antimicrobial activity against Gram-positive and Gram-negative bacteria and no obvious cytotoxicity; and compared with Ac-SK-29, mutant 2 has improved antimicrobial activity under high temperature and trypsin treatment conditions.
[0112] In some embodiments, in the antimicrobial peptide represented by formula (I), R1 is -Ac, R2 is -NH2, X4 is His, X6 is Phe, X8 is Lys, and X... 12 For Lys, X 13 For Phe, X16 For Trp, X 19 For Lys, X 21 For Phe, X 25 The antimicrobial peptide has the amino acid sequence shown in SEQ ID NO:4. The antimicrobial peptide with the sequence shown in SEQ ID NO:4 (hereinafter referred to as: mutant 3) exhibits high antimicrobial activity against both Gram-positive and Gram-negative bacteria, without significant cytotoxicity; and compared with Ac-SK-29, mutant 3 shows significantly enhanced antimicrobial activity under high temperature and trypsin treatment conditions, and relatively high antimicrobial activity under plasma conditions.
[0113] In some embodiments, in the antimicrobial peptide represented by formula (I), R1 is -Ac, R2 is -NH2, X4 is Lys, X6 is Phe, X8 is Arg, and X... 12 For Lys, X 13 For Phe, X 16 For Trp, X 19 For Lys, X 21 For Phe, X 25 The antimicrobial peptide is His. It has the amino acid sequence shown in SEQ ID NO:5. The antimicrobial peptide with the sequence shown in SEQ ID NO:5 (hereinafter referred to as: mutant 4) has high antimicrobial activity against Gram-positive and Gram-negative bacteria and no obvious cytotoxicity; and compared with Ac-SK-29, mutant 4 has improved antimicrobial activity under the conditions of high temperature of 100°C and 4 μg / mL trypsin, and significantly improved antimicrobial activity under the conditions of high temperature of 100°C and 10 μg / mL trypsin.
[0114] In some embodiments, in the antimicrobial peptide represented by formula (I), R1 is -Ac, R2 is -NH2, X4 is Lys, X6 is Phe, X8 is Arg, and X... 12 For Lys, X 13 For Phe, X 16 For Phe, X 19 For Lys, X 21 For Phe, X 25 The antimicrobial peptide is Arg. It has the amino acid sequence shown in SEQ ID NO:6. The antimicrobial peptide with the sequence shown in SEQ ID NO:6 (hereinafter referred to as: mutant 5) exhibits high antimicrobial activity against both Gram-positive and Gram-negative bacteria, without significant cytotoxicity; and compared to Ac-SK-29, mutant 5 shows enhanced antimicrobial activity under high temperature and trypsin treatment conditions.
[0115] In some embodiments, in the antimicrobial peptide represented by formula (I), R1 is -Ac, R2 is -NH2, X4 is Lys, X6 is Phe, X8 is Arg, and X... 12 For Arg, X 13 For Trp, X 16 For Phe, X 19 For Lys, X 21 For Phe, X 25 The antimicrobial peptide is Arg. It has the amino acid sequence shown in SEQ ID NO:7. The antimicrobial peptide with the sequence shown in SEQ ID NO:7 (hereinafter referred to as: mutant 6) exhibits high antimicrobial activity against both Gram-positive and Gram-negative bacteria, without significant cytotoxicity; and compared to Ac-SK-29, mutant 6 shows significantly enhanced antimicrobial activity under conditions of 100°C and 10 μg / mL trypsin.
[0116] In some embodiments, in the antimicrobial peptide represented by formula (I), R1 is -Ac, R2 is -NH2, X4 is Arg, X6 is Phe, X8 is Arg, and X... 12 For Arg, X 13 For Trp, X 16 For Phe, X 19 For Lys, X 21 For Trp, X 25 The antimicrobial peptide is Arg. It has the amino acid sequence shown in SEQ ID NO:8. The antimicrobial peptide with the sequence shown in SEQ ID NO:8 (hereinafter referred to as: mutant 7) exhibits high antimicrobial activity against both Gram-positive and Gram-negative bacteria, without significant cytotoxicity; and compared to Ac-SK-29, mutant 7 shows significantly enhanced antimicrobial activity under high temperature, 4 μg / mL trypsin, and plasma treatment conditions.
[0117] In some embodiments, in the antimicrobial peptide represented by formula (I), R1 is -Ac, R2 is -NH2, X4 is Arg, X6 is Trp, X8 is Arg, and X... 12 For Arg, X 13 For Phe, X 16 For Phe, X 19 For Lys, X 21 For Trp, X 25 The antimicrobial peptide is Arg. It has the amino acid sequence shown in SEQ ID NO:9. The antimicrobial peptide with the sequence shown in SEQ ID NO:9 (hereinafter referred to as: mutant 8) exhibits high antimicrobial activity against both Gram-positive and Gram-negative bacteria, without significant cytotoxicity; and compared to Ac-SK-29, mutant 8 shows significantly enhanced antimicrobial activity under high temperature and trypsin treatment conditions.
[0118] In some embodiments, the antimicrobial peptide may also include added, deleted, or substituted amino acids at one or more positions of the sequence shown in SEQ ID NO: 1 that do not affect protein activity. It is well known that changing a few amino acid residues in certain regions of a polypeptide, such as non-critical regions, does not substantially alter its biological activity; for example, appropriately replacing, adding, or deleting certain amino acids results in a sequence that does not affect its activity.
[0119] For example, the mutant has mutated amino acids at positions 1, 2, 3, 4, 5, etc., of the sequence shown in SEQ ID NO: 1. Furthermore, each mutated amino acid can be independently located at the N-terminus, C-terminus, or interior of the sequence shown in SEQ ID NO: 1, and the mutation mode of the amino acid at each position can be independently selected from substitution, addition, or deletion.
[0120] In some embodiments, an amino acid at one or more positions of the antimicrobial peptide represented by formula (I) is linked to a modifying group. In this disclosure, the modification of the amino acid can be functional group modification, intramolecular covalent bonding (e.g., cyclization between side chains), methylation, acylation, ubiquitination, phosphorylation, aminohexanation, biotinylation, etc.; it can also include substitution to form a non-natural compound, and / or the addition of one or more amino acids to the carboxyl terminus and / or amino terminus of an amino acid in a natural sequence.
[0121] The modifying molecules in this disclosure are selected from one or more combinations of the following: fatty acids, polymers, fluorescent compounds, nucleotides, and drug molecules. In addition, the modifying molecules may also be cholesterol, albumin and fragments thereof, albumin-binding materials, polymers of specific amino acid repeating units, antibodies, antibody fragments, FcRn-binding materials, in vivo connective tissue or its derivatives, nucleotides, fibronectin, transferrin, sugars, heparin, elastin, etc.
[0122] Examples of polymers may be selected from those polymers including: polyethylene glycol, polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ether, biodegradable polymers, lipid polymers, chitin, hyaluronic acid, oligonucleotides, and combinations thereof, but are not specifically limited thereto.
[0123] By linking and modifying molecules to the amino acids of antimicrobial peptides, the antimicrobial activity and stability of antimicrobial peptides can be further improved, or antimicrobial peptides with special application activities can be developed, thus further expanding the clinical application prospects of antimicrobial peptides.
[0124] In some embodiments, an amino acid at any one or more positions of the antimicrobial peptide represented by formula (I) is linked to a drug molecule. The amino acid linked to the drug molecule may be a lysine residue at any one or more positions of the antimicrobial peptide represented by formula (I). The drug molecule in this disclosure is selected from one or more combinations of the following: antibodies, antibody fragments, and antibiotics.
[0125] In this disclosure, drug molecules can be directly linked to the side chains of amino acids in antimicrobial peptides, or linked to the side chains of amino acids in antimicrobial peptides via a linker. Exemplarily, a drug molecule is linked to an N-terminal amino acid in an antimicrobial peptide via a linker, forming a drug molecule-linker-antimicrobial peptide linking structure. The linker can be any type of molecule in the art capable of linking a drug molecule to an antimicrobial peptide.
[0126] The antibodies and antibody fragments in this disclosure include natural and artificial antibodies covering a wide range of structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), single-chain antibodies (e.g., scFv), intact antibodies, Fv, Fab, Fab', Fab'-SH, F(ab')2; linear antibodies; single-domain antibodies; bivalent or bispecific antibodies or fragments thereof; camelid antibodies; and bispecific or multispecific antibodies formed from antibody fragments.
[0127] In this disclosure, drug molecules are covalently bound to the amino acids of antimicrobial peptides, thereby synergistically enhancing the antimicrobial activity, stability, and specificity of the drug molecules and antimicrobial peptides, and reducing the potential adverse risks associated with the use of antimicrobial peptides.
[0128] Application of antimicrobial peptides or compositions
[0129] Antimicrobial peptides or compositions are used in the preparation of medicaments for the prevention or treatment of microbial infections. In some specific embodiments, the microbial infection is a bacterial infection. In some specific embodiments, the bacterial infection is selected from Gram-negative bacterial infections or Gram-positive bacterial infections. In some more specific embodiments, the bacterial infection is a multidrug-resistant bacterial infection. Through the good and stable antimicrobial activity and high biocompatibility of antimicrobial peptides, they exert broad-spectrum bacteriostatic and bactericidal effects, achieving clinical treatment against multidrug-resistant bacteria.
[0130] In this disclosure, the antimicrobial peptides or compositions exhibit synergistic effects against both Gram-negative and Gram-positive bacteria. In some embodiments, the antimicrobial peptides or compositions are used for the prevention or treatment of infections caused by one or more of the following bacteria: *Escherichia coli*, *Vibrio anguillarum*, *Aeromonas hydrophila*, *Staphylococcus aureus*, *Bacillus subtilis*, *Klebsiella pneumoniae*, and *Acinetobacter baumannii*. In other embodiments, the antimicrobial peptides or compositions can also be used for the prevention or treatment of other types of bacteria.
[0131] For example, antimicrobial peptides or compositions are suitable for the treatment of one or more of the following microbial infections:
[0132] Escherichia coli(ATCC 25922), Vibrio anguillarum(ATCC 43308), Aeromonashydrophilia 35654(ATCC 35654), Staphylococcus aureus 25923(ATCC 25923), Bacillus subtilis 6633(ATCC 6633), Escherichia coli 577 (ATCC 577), Klebsiellapneumoniae 2182 (ATCC 2182), Acinetobacter baumannii 7225 (ATCC 7225).
[0133] method
[0134] The method for inhibiting or killing bacteria disclosed herein involves contacting bacteria with an antimicrobial peptide or a composition containing an antimicrobial peptide, utilizing the broad-spectrum antimicrobial effect of the antimicrobial peptide to provide a positive and effective treatment for bacterial infections, especially those caused by drug-resistant bacteria.
[0135] In some embodiments, this disclosure provides methods for preventing or treating diseases, including administering an antimicrobial peptide or composition provided by this disclosure to a subject.
[0136] In some embodiments, the disease is caused by a microbial infection. This bacterial infection can include infections caused by non-drug-resistant bacteria as well as infections caused by drug-resistant bacteria. In some specific embodiments, the bacterial infection is selected from infections caused by Gram-negative bacteria or Gram-positive bacteria. In some more specific embodiments, the bacterial infection is an infection caused by multidrug-resistant bacteria. Through the highly efficient and stable antibacterial and bactericidal effects of antimicrobial peptides, they can be used to prevent and treat bacterial infections, especially those caused by drug-resistant bacteria, providing a positive and effective treatment strategy for clinical treatment.
[0137] In this disclosure, the antimicrobial peptides or compositions exhibit synergistic effects against both Gram-negative and Gram-positive bacteria. In some embodiments, the antimicrobial peptides or compositions are used for the prevention or treatment of infections caused by one or more of the following bacteria: *Escherichia coli*, *Vibrio anguillarum*, *Aeromonas hydrophila*, *Staphylococcus aureus*, *Bacillus subtilis*, *Klebsiella pneumoniae*, and *Acinetobacter baumannii*. In other embodiments, the antimicrobial peptides or compositions can also be used for the prevention or treatment of other types of bacteria.
[0138] For example, antimicrobial peptides or compositions are suitable for the prevention or treatment of one or more microbial infections:
[0139] Escherichia coli(ATCC 25922), Vibrio anguillarum(ATCC 43308), Aeromonashydrophilia 35654(ATCC 35654), Staphylococcus aureus 25923(ATCC 25923), Bacillus subtilis 6633(ATCC 6633), Escherichia coli 577 (ATCC 577), Klebsiellapneumoniae 2182 (ATCC 2182), Acinetobacter baumannii 7225 (ATCC 7225).
[0140] Example
[0141] Other objects, features, and advantages of this disclosure will become apparent from the following detailed description. However, it should be understood that the detailed description and specific embodiments (although illustrating specific implementations of this disclosure) are given for illustrative purposes only, as various changes and modifications that can be made within the spirit and scope of this disclosure will become apparent to those skilled in the art upon reading this detailed description.
[0142] The following description is based on specific embodiments. The reagents and samples are commercially available or otherwise readily available to the public; they are merely examples and not the only ones applicable to this invention. Other suitable tools and biological materials can be substituted. The experimental procedures involved can be performed according to the conditions and methods described in *Molecular Cloning: A Laboratory Manual (Third Edition)* (Science Press, 2002), and according to the manufacturer's instructions for commercially available enzymes and reagent kits. Other experimental methods not described in detail are conventional methods well-known to those skilled in the art unless otherwise specified.
[0143] The experimental materials used in the following examples are shown below:
[0144] 1. Strains
[0145] The strains used to screen for the antimicrobial activity of antimicrobial peptides were: Gram-negative Escherichia coli 25922 (ATCC 25922, E. coli 25922), Vibrio anguillarum 43308 (ATCC 43308, V. anguillarum 43308), Aeromonas hydrophilia 35654 (ATCC 35654, A. hydrophila 35654), and Gram-positive Staphylococcus aureus 25923 (ATCC 25923, S. aureus 25923) and Bacillus subtilis 6633 (ATCC 6633, B. subtilis 6633). All five strains are drug-sensitive. A. hydrophila 35654 was obtained from the School of Life Sciences, Shandong University, while the other four were obtained from our laboratory.
[0146] The three pathogenic multidrug-resistant (MDR) bacterial columns isolated clinically were: *Escherichia coli* 577 (ATCC 577, E. coli 577), *Klebsiella pneumoniae* 2182 (ATCC 2182, K. pneumoniae 2182), and *Acinetobacter baumannii* 7225 (ATCC 7225, A. baumannii 7225). *E. coli* 577 and *K. pneumoniae* 2182 were donated to the Medical College of Qingdao University, and *A. baumannii* 7225 was donated to Qingdao Municipal Hospital.
[0147] 2. Antimicrobial peptides
[0148] Antimicrobial peptides and their mutants were obtained through artificial chemical synthesis. The carboxyl terminus of the peptides was amidated, resulting in a product purity greater than 95%. After passing quality control, the synthesized modified antimicrobial peptides were dissolved in 1% (v / v) 2,2,2-trifluoroethanol (TFE) to prepare a stock solution with a final concentration of 2 mg / mL. The stock solution was then aliquoted and stored at -80°C for later use.
[0149] The amino acid sequences of the antimicrobial peptides involved in the following examples are shown in Table 1 below:
[0150] Table 1
[0151]
[0152]
[0153] Example 1: Cell lines and their culture
[0154] 1.1 Experimental Procedure
[0155] This study used mouse macrophage RAW264.7 cell line (ATCC TIB-71) as experimental material, which was cultured in DMEM medium containing 10% FBS at 37°C and 5% CO2.
[0156] (1) Cell resuscitation
[0157] Frozen cells were stored in a liquid nitrogen tank in the laboratory. Before cell thawing, the water bath was preheated to 37°C. The frozen cells were then removed from the liquid nitrogen and transferred to the water bath for rapid thawing with agitation. The thawed cell suspension was transferred to a new sterile centrifuge tube, 4 mL of fresh culture medium was added, and the cells were thoroughly mixed by pipetting. The tube was centrifuged at 1000 rpm for 4 minutes at room temperature, and the supernatant was discarded. 2 mL of culture medium was added to the centrifuge tube, and the cell plaques were agitated and mixed repeatedly by pipetting. The cell suspension was then transferred to a new cell culture flask. 3 mL of fresh culture medium was added to the flask, and the flask was gently shaken to evenly distribute the cell suspension on the bottom. The cells were then transferred to an incubator for overnight culture, and the cell status was observed the next day.
[0158] (2) Cell passage
[0159] When cells reach 70%–80% confluence in the culture flask, passage them. Preheat sterile PBS, culture medium, and trypsin. Aspirate and discard the existing culture medium from the flask, and wash 1–2 times with 2 mL of sterile PBS to remove excess medium and suspended cells. Then add 1 mL of trypsin and digest the cells for 5 min at room temperature. After observing large cell detachments, add 4 mL of culture medium to stop the reaction, and repeatedly rinse the flask walls to ensure all cells detach into the medium. Depending on the cell count, aliquot the cells at a ratio of 1:5 or 1:6, and replenish the culture medium to 5 mL. After passage, place the cells in an incubator for further culture.
[0160] (3) Cell cryopreservation
[0161] To ensure cell viability, cells passaged to a certain stage were cryopreserved. A cell cryopreservation solution was prepared in advance using FBS and DMSO at a ratio of 9:1. Cells were detached from the culture flask wall, and the cell suspension was transferred to a centrifuge tube. The tube was centrifuged at 1000 rpm for 4 minutes, and the supernatant was discarded. 1 mL of cryopreservation solution was added to the tube, and the mixture was thoroughly mixed by pipetting. The mixture was then transferred to cryovials and placed in a temperature-programmed cooling box for gradient cooling. Finally, the cells were transferred to a liquid ammonia tank for storage.
[0162] Example 2: Design and Synthesis of Pt5 Modified Peptides
[0163] 2.1 Experimental Procedure
[0164] The theoretical molecular weight, isoelectric point, and charge of Pt5 and its derived peptides were analyzed using the protein physicochemical property analysis platform ProtParam tool, APD3, and the antimicrobial peptide database.
[0165] ProtParam tool for analyzing the physicochemical properties of proteins:
[0166] ExPASy Proteomics Server,http: / / www.expasy.org / tools / protparam.html
[0167] APD3http: / / aps.unmc.edu / AP / prediction / prediction_main.php
[0168] Antimicrobial peptide database: http: / / aps.unmc.edu / AP / main.php
[0169] Protein structure prediction
[0170] The secondary and tertiary structures of the modified peptides were predicted using prediction tools Jpred, Predict Protein Server, and QUARK ONLINE.
[0171] Jpred peptide secondary structure prediction: http: / / www.compbio.dundee.ac.uk / www-jpred / index.html
[0172] Predict Protein Server for peptide secondary structure prediction: https: / / predictprotein.org /
[0173] QUARK ONLINE Peptide Tertiary Structure Prediction: http: / / zhanglab.ccmb.med.umich.edu / QUARK /
[0174] Spiral wheel analysis
[0175] Helical Wheel Projections, an online prediction tool, was used to construct helical wheel simulations of peptides for amphiphilicity and hydrophobicity analysis. The helical wheel prediction software, Helical Wheel Projections, was used to perform this analysis.
[0176] 2.2 Experimental Results:
[0177] Structural predictions of Pt5-1a, Pt5-1b, and Ac-SK-29 revealed that all three exhibited an α-helical structure, with Ac-SK-29 exhibiting the best helicity. Figure 1 Compared to the template peptide Pt5-1, the hydrophobicity of the modified peptide Pt5-1a increased from 31% to 37%, the positive charge of Pt5-1b increased from +5 to +10, and Ac-SK-29 showed improvements in both hydrophobicity and positive charge.
[0178] Example 3: Screening for antibacterial activity of Pt5 modified peptides
[0179] 3.1 Experimental Procedure:
[0180] Determination of the antibacterial activity of modified peptides using the liquid antibacterial assay
[0181] The derived peptides were serially diluted with PBS to a series of different concentrations, resulting in a protein concentration gradient ranging from 0.1 μM to 20.0 μM in the mixture. Each mixture contained 480 μL of fresh LB liquid medium and 30 μL of 3 × 10⁻⁶ protein solution. 6 CFU / mL bacterial suspension and 90 μL protein solutions of different concentrations were mixed thoroughly and divided into three equal portions as three parallel samples, which were then added to 96-well cell culture plates. PBS solution was used as a negative control instead of the protein solution. The 96-well cell culture plates were incubated at 37°C for 10 h. The moment the 96-well plate was placed in the incubator was taken as time 0. Every 1 h, the cell culture plates were removed, and the absorbance of each well was measured using a microplate reader. Based on the absorbance changes, a bacterial growth curve was obtained to determine the antibacterial activity and minimum inhibitory concentration (MIC) of the peptide. Repeated-measures ANOVA was used to compare the effects of Ac-SK-29 at concentrations of 0.6 μM and 0.9 μM against Gram-negative and Gram-positive bacteria, with p < 0.05 considered statistically significant.
[0182] 3.2 Experimental Results:
[0183] like Figures 2-1 to 2-3 The results showed that the modified antimicrobial peptides Pt5-1a, Pt5-1b, and Ac-SK-29 all exhibited antibacterial activity against five drug-sensitive bacterial strains. Pt5-1a had MICs of 4.8 μM, 5.4 μM, and 4.2 μM against Gram-negative bacteria E. coli 25922, V. anguillarum 43308, and A. hydrophila 35654, respectively, and a MIC of 5.4 μM against Gram-positive bacteria S. aureus 25923 and B. subtilis 6633. The MICs of Pt5-1b against Gram-negative bacteria E. coli 25922, V. anguillarum 43308, and A. hydrophila 35654 were 4.2 μM, 5.4 μM, and 4.2 μM, respectively, and the MIC against Gram-positive bacteria S. aureus 25923 and B. subtilis 6633 was 5.4 μM. The MICs of Ac-SK-29 against Gram-negative bacteria E. coli 25922, V. anguillarum 43308, and A. hydrophila 35654 were 1.8 μM, 1.2 μM, and 1.2 μM, respectively, and the MICs against Gram-positive bacteria S. aureus 25923 and B. subtilis 6633 were 1.2 μM and 2.4 μM, respectively.
[0184] like Figures 3-1 to 3-2 The results showed that Pt5-1a and Pt5-1b did not exhibit antibacterial activity at concentrations greater than 20 μM, therefore it is concluded that Pt5-1a and Pt5-1b have no antibacterial effect against this pathogenic drug-resistant bacterium. Ac-SK-29, however, showed some antibacterial effect against these three pathogenic drug-resistant bacteria, with a MIC of 4.8 μM for all three strains.
[0185] Example 4: Detection of antibacterial activity of modified peptide Ac-SK-29 under various conditions
[0186] 4.1 Experimental Procedure:
[0187] Through liquid antibacterial experiments, this embodiment found that the modified peptide Ac-SK-29 exhibited the strongest antibacterial activity and was effective against pathogenic drug-resistant bacteria. To further investigate the conditions of action of Ac-SK-29 and test its antibacterial activity under extreme environments, this embodiment designed liquid antibacterial experiments on Ac-SK-29 under high temperature, plasma, trypsin, acidic, and alkaline conditions. Using E. coli 25922 and S. aureus 25923 as experimental materials, after activation, culture, and dilution, a final concentration of 3 × 10⁻⁶ was obtained. 6Prepare a bacterial culture at cfu / mL for later use.
[0188] Antibacterial activity of Ac-SK-29 under high temperature treatment
[0189] To investigate the effect of high temperature on the antibacterial ability of Ac-SK-29, this embodiment conducted a liquid antibacterial experiment on Ac-SK-29 after high temperature treatment.
[0190] (1) High temperature pretreatment Ac-SK-29
[0191] Prepare two tubes of Ac-SK-29 solution and place them in metal baths at 50℃ and 100℃ respectively, heating for 30 min. Then, centrifuge at 4000×g for 5 min at room temperature to check for precipitation. Adjust the Ac-SK-29 concentration in the 96 wells to a final concentration of 1×MIC, 1.5×MIC, and 2×MIC.
[0192] (2) Liquid antibacterial test
[0193] The following grouping is designed:
[0194] Table 2
[0195]
[0196] After each group was prepared, it was mixed with 480 μL of LB liquid medium, thoroughly mixed, and then divided into 3 equal portions as 3 parallel samples, which were injected into 96-well plates. The 96-well plates were then incubated in a 37°C incubator. The absorbance was measured every 1 hour from the start of incubation to 0, for a total of 10 measurements.
[0197] Antibacterial activity of Ac-SK-29 after plasma treatment
[0198] (1) Preparation of plasma
[0199] Fresh human blood was collected and stored in anticoagulant tubes containing EDTA. The blood was centrifuged at 1000×g for 10 min at room temperature, retaining the supernatant (pale yellow) liquid and discarding the basal cells. The blood used in the experiment came from the Affiliated Hospital of Qingdao University.
[0200] (2) Detection of plasma's own antibacterial effect
[0201] Plasma, as the extracellular matrix of blood, contains a large number of plasma proteins and is an important medium for transporting secreted products of the body. To eliminate the influence of the potential antibacterial capacity of plasma itself on the antibacterial effect of Ac-SK-29, the following grouping was designed in this embodiment:
[0202] Table 3
[0203]
[0204] (3) Detection of antibacterial activity of Ac-SK-29 after plasma conditioning
[0205] The test in step (2) showed that the plasma had no significant antibacterial activity against E. coli 25922 and S. aureus 25923, so the next step of the experiment was carried out.
[0206] PBS and plasma were mixed at a 1:10 ratio and named Solution X, serving as a control. A high-concentration Ac-SK-29 solution was mixed with plasma at a 1:10 ratio and named Solution Y. After standing at room temperature for 1 hour, the solutions were centrifuged at 1000×g for 10 minutes to observe for precipitation. Simultaneously, the Ac-SK-29 concentration was adjusted to a final concentration of 1×MIC, 1.5×MIC, and 2×MIC in the 96 wells. The following groupings were then used for detection:
[0207] Table 4
[0208]
[0209] Antibacterial activity of Ac-SK-29 under acidic / alkaline conditions
[0210] Studies have shown that the effectiveness of antimicrobial peptides may be affected by the pH of their environment. To investigate the effects of acidic and alkaline conditions on Ac-SK-29, this embodiment adjusted the ratio of phosphate buffer to obtain buffer solutions with pH values of 5.6 and 8.0, respectively.
[0211] (1) The effect of buffer pH on bacteria
[0212] To rule out the effects of changes in buffer pH on bacteria, the following pre-experiment was designed in this embodiment:
[0213] Table 5
[0214]
[0215] (2) Antibacterial test of Ac-SK-29 liquid after acid / alkaline treatment
[0216] Dissolve Ac-SK-29 dry powder in PB buffer solutions at pH 5.6 and pH 8.0, let stand at room temperature for 30 min, then centrifuge at 4000×g for 5 min at room temperature to observe precipitation. Adjust the Ac-SK-29 concentration in the 96 wells to a final concentration of 1×MIC, 1.5×MIC, and 2×MIC.
[0217] The following grouping is designed:
[0218] Table 6: ① E. coli group 25922
[0219]
[0220] Table 7: ②S. aureus group 25923
[0221]
[0222] Antibacterial activity of Ac-SK-29 under trypsin treatment
[0223] Protease degradation is a major problem affecting the development of antimicrobial peptides. To test the ability of the antimicrobial peptide Ac-SK-29 to resist protease degradation, two antimicrobial peptides were treated with trypsin, and then the changes in the inhibitory MIC were measured.
[0224] Table 8: ① E. coli group 25922
[0225]
[0226]
[0227] Table 9: ②S. aureus group 25923
[0228]
[0229] 4.2 Experimental Results
[0230] Antibacterial activity of Ac-SK-29 under high temperature treatment
[0231] Ac-SK-29 solutions at final concentrations of 1×MIC, 1.5×MIC, and 2×MIC were treated at 50℃ and 100℃ for 30 min, respectively. The peptide solutions remained clear, without impurities or flocculent precipitates, and no obvious precipitate was observed at the bottom of the tubes after centrifugation. Liquid antibacterial experiments showed that the MICs of Ac-SK-29 against E. coli 25922 and S. aureus 25923 remained unchanged after treatment at 50℃, remaining at 1.8 μM and 1.2 μM, respectively. However, the MICs of Ac-SK-29 against E. coli 25922 and S. aureus 25923 after treatment at 100℃ increased to 1.5 times that at room temperature, indicating that high-temperature treatment at 100℃ has a certain impact on the activity of Ac-SK-29. Figure 4 ).
[0232] Antibacterial activity of Ac-SK-29 under plasma conditioned conditions
[0233] Plasma contains solutes and is pale yellow in color. Its absorbance is slightly higher than that of the buffer solution, but the difference is not statistically significant and can be ignored. Preliminary results showed that plasma could slightly delay bacterial reproduction but could not inhibit bacterial growth. Furthermore, the absorbance of the plasma-PBS mixture did not change significantly over time, indicating that plasma has no significant inhibitory effect on bacteria, and its own absorbance is stable and will not affect the system, allowing for further experiments. Antibacterial assays showed that the MICs of Ac-SK-29 against E. coli 25922 and S. aureus 25923 were not changed under plasma treatment conditions, indicating that plasma does not interfere with the antibacterial activity of Ac-SK-29. Figure 5 ).
[0234] Antibacterial activity of Ac-SK-29 under acidic and alkaline conditions
[0235] Preliminary results showed that incubating E. coli 25922 and S. aureus 25923 with buffers at pH 5.6 and 8.0, respectively, did not significantly alter the growth curves of the two bacteria compared to PBS buffer at pH 7.4. Therefore, it was concluded that changes in buffer pH had no effect on bacterial growth, and subsequent experiments could proceed. After dissolving Ac-SK-29 in buffers at pH 5.6 and 8.0 and allowing them to stand for a period of time, the solutions remained clear and transparent, and no precipitate formed after centrifugation, proving that Ac-SK-29 is soluble in buffers at pH 5.6 and 8.0 and is not easily precipitated or damaged. Liquid antibacterial experiments showed that the MIC of Ac-SK-29 against E. coli 25922 and S. aureus 25923 did not change compared to the pH 7.4 buffer. Figure 6 ).
[0236] Antibacterial activity of Ac-SK-29 under trypsin-treated conditions
[0237] The results are shown in the table. When the trypsin concentration was in the range of 0-4 μg / mL, the antibacterial activity of the antimicrobial peptide Ac-SK-29 did not change significantly. When the trypsin concentration was higher than 4 μg / mL, the antimicrobial activity of the antimicrobial peptide began to be affected to some extent. However, when the trypsin concentration increased to 10 μg / mL, the antimicrobial peptide Ac-SK-29 could still maintain good antimicrobial activity, indicating that the antimicrobial peptide Ac-SK-29 was relatively stable under trypsin treatment.
[0238] Example 5: Cytotoxicity and Hemolytic Activity Analysis of Ac-SK-29
[0239] 5.1 Experimental Procedure
[0240] Cytotoxicity assay
[0241] In this experiment, the mouse macrophage RAW264.7 cell line was used as the test cells, and the MTT assay was used to detect the toxic effects of the modified peptide Ac-SK-29 on mammalian cells.
[0242] Mouse macrophages RAW264.7 were cultured in DMEM medium containing 10% FBS at 37°C and 5% CO2. After digestion and resuspending healthy RAW264.7 cells in serum-free DMEM medium, the cell concentration was adjusted to 1 × 10⁻⁶ cells / mL. 6 cells / mL. Take a new sterile 96-well plate and inject 180 μL of cell suspension into each well. Then place the plate in a cell culture incubator and incubate for 2 hours to allow the cells to adhere and grow.
[0243] After complete cell adhesion, Ac-SK-29 solution dissolved in serum-free DMEM medium was added to each well to achieve final Ac-SK-29 concentrations of 5 μM, 10 μM, and 20 μM. The plates were then returned to the cell culture incubator for 4 hours. Pure DMEM was used as a blank control. To detect the effect of amino acid mutations on cytotoxicity, Pt5-1 solution (5 μM, 10 μM, and 20 μM) control groups were set up. Three replicates were prepared for each sample. After 4 hours, 20 μL of MTT solution (5 mg / mL) was added to each well, and the plates were cultured for another 4 hours. After 4 hours, the liquid in the wells was discarded, and 150 μL of DMSO was added to each well. The plates were then transferred to a microplate reader to measure the absorbance of each well at a wavelength of 492 nm.
[0244] Cell viability was calculated as follows: Cell viability = (OD value of treatment group / OD value of control group) × 100% (n = 3). Three replicates were set up for each group in each experiment, and the experiment was repeated three times. The results were analyzed using one-way ANOVA, with p < 0.05 considered statistically significant.
[0245] hemolytic test
[0246] To test whether Ac-SK-29 has a hemolytic effect on normal cells, a hemolysis experiment was conducted.
[0247] Fresh human blood was collected and stored in a special blood collection tube containing an anticoagulant. The blood used came from the Affiliated Hospital of Qingdao University. The blood was centrifuged at 1000×g for 10 min at room temperature, the supernatant was discarded, and the red blood cells at the bottom were collected. The collected human red blood cells were washed three times with PBS, taking care not to damage the cells. After washing, the human red blood cells were resuspended in PBS to a final concentration of 4% (v / v).
[0248] 200 μL of resuspended human erythrocyte suspension was mixed with 200 μL of Ac-SK-29 solution to achieve final Ac-SK-29 concentrations of 5 μM, 10 μM, and 20 μM. After thorough mixing, the mixture was incubated at 37°C for 1 h. Blank control (PBS), negative control (BSA solution, 20 μM), and positive control (0.1% Triton X-100) were provided. To investigate the effect of altered amino acids on cell hemolysis, Pt5-1 solution (5 μM, 10 μM, and 20 μM) was used as the pre-mutation control. After 1 h, the incubated cells were removed and centrifuged at 1000 × g for 10 min at room temperature. 200 μL of the supernatant was injected into each well of a sterile 96-well plate. The absorbance of each well was read using a microplate reader at a wavelength of 540 nm. Each experiment was conducted with three parallel samples, and the experiment was repeated at least three times. The results were analyzed for significance using the two-way ANOVA method, with p < 0.05 considered significant.
[0249] 5.1 Experimental Results
[0250] Ac-SK-29 cytotoxicity
[0251] This experiment used RAW264.7 mouse macrophage cell line as experimental material. The cell viability under Ac-SK-29 treatment was determined by the MTT assay to detect whether Ac-SK-29 has toxic effects. The experimental results are shown in the table below. Within the tested concentration range, Ac-SK-29 did not show significant toxic damage to RAW264.7 mouse macrophages, and the cell viability was not statistically significantly different from that of the truncated parent antimicrobial peptide Pt5-1 (F = 2.945, p = 0.058). Therefore, it can be inferred that Ac-SK-29 does not have significant toxicity to normal mammalian tissue cells cultured in vitro.
[0252] Table 10:
[0253]
[0254] hemolytic activity of Ac-SK-29
[0255] This experiment used human erythrocytes as experimental material to detect the hemolytic effect of Ac-SK-29 on mammalian cells. The experimental results are as follows: Figure 7 As shown, Ac-SK-29 did not exhibit significant hemolytic activity at concentrations as high as 20 μM compared to the positive control group. Furthermore, it showed no significant difference compared to the truncated parental antimicrobial peptide Pt5-1 (F = 1.649, p = 0.205). Therefore, it can be concluded that Ac-SK-29 has no hemolytic activity against mammalian blood cells.
[0256] Example 6: Determination of antibacterial activity and stability of mutant 1
[0257] This embodiment provides a mutant 1 of the antimicrobial peptide Ac-SK-29, the amino acid sequence of which is shown in SEQ ID NO:2. The mutant 1 is synthesized by conventional solid-phase synthesis, purified by semi-preparative liquid chromatography, and analyzed and confirmed by LC-MS.
[0258] Determination of the antibacterial activity of modified peptides using the liquid antibacterial assay
[0259] The mutant peptide was serially diluted with PBS solution to a series of different concentrations, resulting in a protein concentration gradient ranging from 0.1 μM to 20.0 μM in the mixture. Each mixture contained 480 μL of fresh LB liquid medium and 30 μL of 3 × 10⁻⁶ protein solution. 6 CFU / mL bacterial suspension and 90 μL protein solutions of different concentrations were mixed thoroughly and divided into three equal portions as three replicates, which were then added to 96-well cell culture plates. PBS solution was used as a negative control instead of the protein solution. The 96-well cell culture plates were incubated at 37°C for 10 hours. Taking the moment the 96-well plate was placed in the incubator as time 0, the cell culture plates were removed every 1 hour, and the absorbance of each well was measured using a microplate reader. Based on the absorbance changes, a bacterial growth curve was obtained, and the antibacterial activity and minimum inhibitory concentration (MIC) of the peptides were determined.
[0260] The designed antimicrobial peptide Ac-SK-29 mutant 1 exhibited excellent antibacterial activity against five drug-sensitive bacterial strains. The MICs for Gram-negative bacteria were 1.8 μM, 1.2 μM, and 1.2 μM for Escherichia coli (ATCC 25922), Vibrio anguillarum (ATCC 43308), and A. hydrophila 35654, respectively; and 1.2 μM and 2.4 μM for Gram-positive bacteria Staphylococcus aureus (ATCC 25923) and Bacillus subtilis (ATCC 6633), respectively. For multidrug-resistant bacteria: Escherichia coli 577 (ATCC 577); Klebsiella pneumoniae 2182 (ATCC 2182); Acinetobacter baumannii 7225 (ATCC 7225), the MICs were 4.8 μM, 4.8 μM, and 4.8 μM, respectively, showing good inhibitory performance against drug-resistant bacteria.
[0261] The comparison of mutant 1 in terms of high temperature, plasma, trypsin, cytotoxicity, and hemolysis was conducted using the experimental methods and conditions described above, and the results are as follows:
[0262] Table 11
[0263]
[0264] Example 7: Determination of antibacterial activity and stability of mutant 2
[0265] The specific implementation method and experimental process of the liquid antibacterial method are the same as the detection steps of mutant 1 in Example 6.
[0266] The designed antimicrobial peptide Ac-SK-29 mutant 2 exhibited good antibacterial activity against five drug-sensitive bacterial strains. The MICs for Gram-negative bacteria were 1.9 μM, 1.3 μM, and 1.6 μM for Escherichia coli (ATCC 25922), Vibrio anguillarum (ATCC 43308), and A. hydrophila 35654, respectively; and 1.5 μM and 2.4 μM for Gram-positive bacteria Staphylococcus aureus (ATCC 25923) and Bacillus subtilis (ATCC 6633), respectively. For multidrug-resistant bacteria, the MICs of Escherichia coli 577 (ATCC 577), Klebsiella pneumoniae 2182 (ATCC 2182), and Acinetobacter baumannii 7225 (ATCC 7225) were 4.8 μM, 5.0 μM, and 5.2 μM, respectively, showing good inhibitory performance against drug-resistant bacteria.
[0267] The comparison of mutant 2 in terms of high temperature, plasma, trypsin, cytotoxicity, and hemolysis was conducted using the experimental methods and conditions described above, and the results are as follows:
[0268] Table 12
[0269]
[0270] Example 8: Determination of antibacterial activity and stability of mutant 3
[0271] The specific implementation method and experimental process of the liquid antibacterial method are the same as the detection steps of mutant 1 in Example 6.
[0272] The designed antimicrobial peptide Ac-SK-29 mutant 3 exhibited good antibacterial activity against five drug-sensitive bacterial strains. The MICs for Gram-negative bacteria were 2.1 μM, 1.7 μM, and 1.6 μM for Escherichia coli (ATCC 25922), Vibrio anguillarum (ATCC 43308), and A. hydrophila 35654, respectively; and 1.2 μM and 2.2 μM for Gram-positive bacteria Staphylococcus aureus (ATCC 25923) and Bacillus subtilis (ATCC 6633), respectively. For multidrug-resistant bacteria, the MICs of Escherichia coli 577 (ATCC 577), Klebsiella pneumoniae 2182 (ATCC 2182), and Acinetobacter baumannii 7225 (ATCC 7225) were 4.9 μM, 5.7 μM, and 5.2 μM, respectively, showing good inhibitory performance against drug-resistant bacteria.
[0273] The comparison of mutant 3 in terms of high temperature, plasma, trypsin, cytotoxicity, and hemolysis was conducted using the experimental methods and conditions described above, and the results are as follows:
[0274] Table 13
[0275]
[0276] Example 9: Determination of antibacterial activity and stability of mutant 4
[0277] The specific implementation method and experimental process of the liquid antibacterial method are the same as the detection steps of mutant 1 in Example 6.
[0278] The designed antimicrobial peptide Ac-SK-29 mutant 4 exhibited good antibacterial activity against five drug-sensitive bacterial strains. The MICs for Gram-negative bacteria were 1.9 μM, 1.7 μM, and 2.0 μM for Escherichia coli (ATCC 25922), Vibrio anguillarum (ATCC 43308), and A. hydrophila 35654, respectively; and 1.4 μM and 2.4 μM for Gram-positive bacteria Staphylococcus aureus (ATCC 25923) and Bacillus subtilis (ATCC 6633), respectively. For multidrug-resistant bacteria, the MICs of Escherichia coli 577 (ATCC 577), Klebsiella pneumoniae 2182 (ATCC 2182), and Acinetobacter baumannii 7225 (ATCC 7225) were 4.6 μM, 4.7 μM, and 5.2 μM, respectively, showing good inhibitory performance against drug-resistant bacteria.
[0279] The comparison of mutant 4 in terms of high temperature, plasma, trypsin, cytotoxicity, and hemolysis was conducted using the experimental methods and conditions described above, and the results are as follows:
[0280] Table 14
[0281]
[0282]
[0283] Example 10: Determination of antibacterial activity and stability of mutant 5
[0284] The specific implementation method and experimental process of the liquid antibacterial method are the same as the detection steps of mutant 1 in Example 6.
[0285] The designed antimicrobial peptide Ac-SK-29 mutant 5 exhibited good antibacterial activity against five drug-sensitive bacterial strains. The MICs for Gram-negative bacteria were 2.1 μM, 1.7 μM, and 2.0 μM for Escherichia coli (ATCC 25922), Vibrio anguillarum (ATCC 43308), and A. hydrophila 35654, respectively; and for Gram-positive bacteria, Staphylococcus aureus (ATCC 25923) and Bacillus subtilis (ATCC 6633), respectively, with MICs of 1.9 μM and 2.2 μM, respectively. For multidrug-resistant bacteria: Escherichia coli 577 (ATCC 577); Klebsiella pneumoniae 2182 (ATCC 2182); Acinetobacter baumannii 7225 (ATCC 7225), the MICs were 4.9 μM, 5.6 μM, and 5.2 μM, respectively, showing good inhibitory performance against drug-resistant bacteria. It was also found that mutant 5 did not show significant changes in antibacterial activity after treatment with high concentrations of trypsin, indicating potential application value.
[0286] The comparison of mutant 5 in terms of high temperature, plasma, trypsin, cytotoxicity, and hemolysis was conducted using the experimental methods and conditions described above, and the results are as follows:
[0287] Table 15
[0288]
[0289] Example 11: Determination of antibacterial activity and stability of mutant 6
[0290] The specific implementation method and experimental process of the liquid antibacterial method are the same as the detection steps of mutant 1 in Example 6.
[0291] The designed antimicrobial peptide Ac-SK-29 mutant 6 exhibited good antibacterial activity against five drug-sensitive bacterial strains. The MICs for Gram-negative bacteria were 1.9 μM, 1.3 μM, and 1.5 μM for Escherichia coli (ATCC 25922), Vibrio anguillarum (ATCC 43308), and A. hydrophila 35654, respectively; and 1.6 μM and 2.3 μM for Gram-positive bacteria Staphylococcus aureus (ATCC 25923) and Bacillus subtilis (ATCC 6633), respectively. For multidrug-resistant bacteria, the MICs of Escherichia coli 577 (ATCC 577), Klebsiella pneumoniae 2182 (ATCC 2182), and Acinetobacter baumannii 7225 (ATCC 7225) were 4.5 μM, 5.1 μM, and 5.0 μM, respectively, showing good inhibitory performance against drug-resistant bacteria.
[0292] The comparison of mutant 6 in terms of high temperature, plasma, trypsin, cytotoxicity, and hemolysis was conducted using the experimental methods and conditions described above, and the results are as follows:
[0293] Table 16
[0294]
[0295]
[0296] Example 12: Determination of antibacterial activity and stability of mutant 7
[0297] The specific implementation method and experimental process of the liquid antibacterial method are the same as the detection steps of mutant 1 in Example 6.
[0298] The designed antimicrobial peptide Ac-SK-29 mutant 7 exhibited good antibacterial activity against five drug-sensitive bacterial strains. The MICs for Gram-negative bacteria were 1.8 μM, 1.2 μM, and 1.9 μM for Escherichia coli (ATCC 25922), Vibrio anguillarum (ATCC 43308), and A. hydrophila 35654, respectively; and for Gram-positive bacteria, Staphylococcus aureus (ATCC 25923) and Bacillus subtilis (ATCC 6633), respectively, were 1.9 μM and 2.2 μM, respectively. For multidrug-resistant bacteria, the MICs of Escherichia coli 577 (ATCC 577), Klebsiella pneumoniae 2182 (ATCC 2182), and Acinetobacter baumannii 7225 (ATCC 7225) were 5.5 μM, 5.6 μM, and 5.3 μM, respectively, showing good inhibitory performance against drug-resistant bacteria.
[0299] The comparison of mutant 7 in terms of high temperature, plasma, trypsin, cytotoxicity, and hemolysis was conducted using the experimental methods and conditions described above, and the results are as follows:
[0300] Table 17
[0301]
[0302] Example 13: Determination of antibacterial activity and stability of mutant 8
[0303] The specific implementation method and experimental process of the liquid antibacterial method are the same as the detection steps of mutant 1 in Example 6.
[0304] The designed antimicrobial peptide Ac-SK-29 mutant 8 exhibited good antibacterial activity against five drug-sensitive bacterial strains. The MICs for Gram-negative bacteria were 1.9 μM, 2.2 μM, and 2.6 μM for Escherichia coli (ATCC 25922), Vibrio anguillarum (ATCC 43308), and A. hydrophila 35654, respectively; and 1.8 μM and 2.7 μM for Gram-positive bacteria Staphylococcus aureus (ATCC 25923) and Bacillus subtilis (ATCC 6633), respectively. For multidrug-resistant bacteria, the MICs of Escherichia coli 577 (ATCC 577), Klebsiella pneumoniae 2182 (ATCC 2182), and Acinetobacter baumannii 7225 (ATCC 7225) were 4.9 μM, 5.0 μM, and 5.0 μM, respectively, showing good inhibitory performance against drug-resistant bacteria.
[0305] The comparison of mutant 8 in terms of high temperature, plasma, trypsin, cytotoxicity, and hemolysis was conducted using the experimental methods and conditions described above, and the results are as follows:
[0306] Table 18
[0307]
[0308] The embodiments described above are merely examples for clearly illustrating the present disclosure and are not intended to limit the implementation of the present disclosure. Those skilled in the art can make other variations or modifications based on the above description. It is neither necessary nor possible to exhaustively describe all possible implementations. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of this disclosure should be included within the scope of protection of the claims of this disclosure. SEQUENCE LISTING <110> Qingdao Blue Valley Polypeptide Biomedical Technology Co., Ltd. <120> Antimicrobial peptides, pharmaceutical compositions containing antimicrobial peptides, and their applications <130> 6C37-2193169I <160> 9 <170> PatentIn version 3.5 <210> 1 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> sequence of Ac-SK-29 <220> <221> MOD_RES <222> (1)..(1) <223> ACETYLATION <220> <221> MOD_RES <222> (29)..(29) <223> AMIDATION <400> 1 Ser Arg Met Lys Lys Trp Ala Lys Ile Ile Glu Lys Trp Arg Lys Trp 1 5 10 15 His Lys Lys Arg Trp Leu Ala His His Ser Ala Thr Lys 20 25 <210> 2 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> sequence of mutant 1 <220> <221> MOD_RES <222> (29)..(29) <223> AMIDATION <400> 2 Ser Arg Met Lys Lys Trp Ala Lys Ile Ile Glu Lys Trp Arg Lys Trp 1 5 10 15 His Lys Lys Arg Trp Leu Ala His His Ser Ala Thr Lys 20 25 <210> 3 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> sequence of mutant 2 <220> <221> MOD_RES <222> (1)..(1) <223> ACETYLATION <220> <221> MOD_RES <222> (29)..(29) <223> AMIDATION <400> 3 Ser Arg Met His Lys Phe Ala Lys Ile Ile Glu Lys Phe Arg Lys Trp 1 5 10 15 His Lys Lys Arg Trp Leu Ala His His Ser Ala Thr Lys 20 25 <210> 4 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> sequence of mutant 3 <220> <221> MOD_RES <222> (1)..(1) <223> ACETYLATION <220> <221> MOD_RES <222> (29)..(29) <223> AMIDATION <400> 4 Ser Arg Met His Lys Phe Ala Lys Ile Ile Glu Lys Phe Arg Lys Trp 1 5 10 15 His Lys Lys Arg Phe Leu Ala His His Ser Ala Thr Lys 20 25 <210> 5 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> sequence of mutant 4 <220> <221> MOD_RES <222> (1)..(1) <223> ACETYLATION <220> <221> MOD_RES <222> (29)..(29) <223> AMIDATION <400> 5 Ser Arg Met Lys Lys Phe Ala Arg Ile Ile Glu Lys Phe Arg Lys Trp 1 5 10 15 His Lys Lys Arg Phe Leu Ala His His Ser Ala Thr Lys 20 25 <210> 6 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> sequence of mutant 5 <220> <221> MOD_RES <222> (1)..(1) <223> ACETYLATION <220> <221> MOD_RES <222> (29)..(29) <223> AMIDATION <400> 6 Ser Arg Met Lys Lys Phe Ala Arg Ile Ile Glu Lys Phe Arg Lys Phe 1 5 10 15 His Lys Lys Arg Phe Leu Ala His Arg Ser Ala Thr Lys 20 25 <210> 7 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> sequence of mutant 6 <220> <221> MOD_RES <222> (1)..(1) <223> ACETYLATION <220> <221> MOD_RES <222> (29)..(29) <223> AMIDATION <400> 7 Ser Arg Met Lys Lys Phe Ala Arg Ile Ile Glu Arg Trp Arg Lys Phe 1 5 10 15 His Lys Lys Arg Phe Leu Ala His Arg Ser Ala Thr Lys 20 25 <210> 8 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> sequence of mutant 7 <220> <221> MOD_RES <222> (1)..(1) <223> ACETYLATION <220> <221> MOD_RES <222> (29)..(29) <223> AMIDATION <400> 8 Ser Arg Met Arg Lys Phe Ala Arg Ile Ile Glu Arg Trp Arg Lys Phe 1 5 10 15 His Lys Lys Arg Trp Leu Ala His Arg Ser Ala Thr Lys 20 25 <210> 9 <211> 29 <212> PRT <213> Artificial Sequence <220> <223> sequence of mutant 8 <220> <221> MOD_RES <222> (1)..(1) <223> ACETYLATION <220> <221> MOD_RES <222> (29)..(29) <223> AMIDATION <400> 9 Ser Arg Met Arg Lys Trp Ala Arg Ile Ile Glu Arg Phe Arg Lys Phe 1 5 10 15 His Lys Lys Arg Trp Leu Ala His Arg Ser Ala Thr Lys 20 25
Claims
1. An antimicrobial peptide as shown in formula (I) or a pharmaceutically acceptable salt thereof: R1-Ser-Arg-Met-X4-Lys-X6-Ala-X8-Ile-Ile-Glu-X 12 -X 13 -Arg-Lys-X 16 -His-Lys-X 19 -Arg-X 21 -Leu-Ala-His-X 25 -Ser-Ala-Thr-Lys-R2(I)? in, R1 is Ac, R2 is NH2; X4 can be selected from the group consisting of Lys, His, and Arg. X6 is selected from Phe; X8 can be selected from the groups consisting of Lys and Arg; X 12 Choose the group consisting of Arg and Lys; X 13 Choose the group consisting of Trp and Phe; X 16 Choose the group consisting of Trp and Phe; X 19 Selected from Lys; X 21 Choose the group consisting of Trp and Phe; X 25 Choose the group consisting of His and Arg; The amino acid sequence of the antimicrobial peptide is shown in any one of SEQ ID NO:3 to SEQ ID NO:
8.
2. A pharmaceutical composition, wherein, The pharmaceutical composition comprises the antimicrobial peptide as described in claim 1 or a pharmaceutically acceptable salt thereof.
3. The pharmaceutical composition according to claim 2, wherein, The pharmaceutical composition also includes one or more pharmaceutically acceptable carriers.
4. The pharmaceutical composition according to claim 3, wherein, The pharmaceutically acceptable carriers include one or more of the following: solvents, solubilizers, cosolvents, emulsifiers, flavoring agents, odorants, colorants, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, pH regulators, stabilizers, surfactants, and preservatives.
5. The use of the antimicrobial peptide of claim 1 or a pharmaceutically acceptable salt thereof, or the use of the pharmaceutical composition of any one of claims 2-4 in the preparation of a medicament for treating microbial infections, wherein, The microbial infection is an infection of one or more bacteria selected from Escherichia coli, Vibrio anguillarum, Aeromonas hydrophila, Staphylococcus aureus, Bacillus subtilis, Klebsiella pneumoniae, and Acinetobacter baumannii.
6. The application according to claim 5, wherein, The microbial infection is selected from one or more of the following microorganisms: Escherichia coli ATCC 25922, Vibrio anguillarum ATCC 43308, Aeromonashydrophila ATCC 35654, Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC6633, Escherichia coli ATCC 577, Klebsiella pneumoniae ATCC 2182, Acinetobacterbaumannii ATCC 7225.
7. A method for inhibiting or killing bacteria in vitro, wherein, The method comprises contacting bacteria with the antimicrobial peptide according to claim 1 or a pharmaceutically acceptable salt thereof, or contacting bacteria with a pharmaceutical composition according to any one of claims 2-4, wherein the bacteria are selected from one or more of Escherichia coli, Vibrio anguillarum, Aeromonas hydrophila, Staphylococcus aureus, Bacillus subtilis, Klebsiella pneumoniae, and Acinetobacter baumannii.
8. The method according to claim 7, wherein, The bacteria are selected from one or more of the following combinations: Escherichia coli ATCC 25922, Vibrio anguillarum ATCC 43308, Aeromonashydrophila ATCC 35654, Staphylococcus aureus ATCC 25923, Bacillus subtilis ATCC6633, Escherichia coli ATCC 577, Klebsiella pneumoniae ATCC 2182, and Acinetobacterbaumannii ATCC 7225.
Citation Information
Patent Citations
Polypeptide Pv26-3 with antimicrobial activity
CN108570102A
